International journal of dermatology|2025|Branyiczky M et al.
PMID: 41174840
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Tirzepatide (Zepbound), a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrates an additive effect, significantly enhancing insulin secretion compared to administering each hormone separate…
BACKGROUND: Obstructive sleep apnea (OSA) is a common condition characterized by repeated airway collapse during sleep, leading to breathing interruptions. OSA increases the risk of developing hypertension, heart disease, stroke, and respiratory comp…
Tirzepatide, an injectable agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, is used to treat type 2 diabetes mellitus and obesity. To our knowledge, there have been few reported cases of drug-induced live…
Type 2 diabetes (T2D), the most common form, is marked by insulin resistance and β-cell failure. β-cell dysfunction under high-glucose-high-lipid (HG-HL) conditions is a key contributor to the progression of T2D. This study evaluates the comparative…
PURPOSE OF REVIEW: This review summarizes research on glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and their relevance in the treatment of benign gynecologic conditions. RECENT FINDINGS: GLP-1 RA use is increasing in popularity in…
Emerging clinical data support the paradoxical notion that glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) agonism and antagonism can provide additive weight loss when combined with a glucagon-like peptide 1 (GLP-1) receptor (GLP-1…
BACKGROUND & AIMS: In the SYNERGY-NASH trial for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis, tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ef…
Obesity confers increased risks of HF, coronary artery disease, and stroke, and weight loss can reduce cardiovascular disease risk. Given emerging evidence of the benefits of semaglutide and tirzepatide in individuals with HFpEF and obesity in concer…
INTRODUCTION: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, produces substantial weight loss and glycaemic improvement in people with and without type 2 diabetes mellitus…
OBJECTIVE: Patients prescribed second-generation antipsychotics (SGA) are at risk of antipsychotic induced weight gain (AIWG). The objective was to estimate weight changes after prescription of incretin-based weight loss medications by category of ex…
BACKGROUND/AIMS: Tirzepatide has been approved for weight loss in adults with obesity. However, real-world data are still needed. This real-world prospective study is among the first to evaluate the short-term metabolic effects of low-dose tirzepatid…
AIMS: The goal of this observational, single-cohort, pre-post study was to describe the association of tirzepatide with glycaemic control and weight loss in patients with type 2 diabetes (T2D) in a US commercially insured population. MATERIALS AND ME…